Philips India’s Bengaluru facility now develops 85% of the global parent’s healthcare AI innovations. The company has invested ₹1750 crore in India to scale R&D and manufacturing, though it operates as an unlisted subsidiary.
Philips India is playing a central role in the global operations of Dutch multinational Royal Philips. The company’s Bengaluru campus has emerged as the primary engine for its international artificial intelligence strategy, with approximately 85% of all AI-based healthcare innovations being designed and developed in India.
This shift in focus towards Indian talent and technology is supported by a substantial capital investment of ₹1750 crore over the last four to five years. The company has directed these funds into its facilities in Bengaluru and Pune, aiming to strengthen not only its software and AI capabilities but also its local manufacturing footprint. One key metric highlighting the scale of this operation is that roughly one in every two medical devices sold by Philips globally now includes software developed in Bengaluru.
Understanding the Unlisted Entity
For Indian investors, it is important to note that Philips India Limited operates as an unlisted subsidiary of the global parent company, Royal Philips (listed on the NYSE as PHG). The Indian entity was delisted from Indian stock exchanges back in 2004. Consequently, the company does not provide the same level of public financial disclosures, such as quarterly profit or revenue breakdowns, as listed companies. This limits the ability of retail investors to directly participate in the Indian entity's growth through the stock market.
Globally, the parent company, Royal Philips, continues to navigate its own corporate developments. On August 11, 2026, the company announced that its largest shareholder, Exor N.V., updated its agreement to potentially increase its stake in the parent organization to 22%, reflecting a significant shift in the global shareholding structure.
AI in Healthcare: Opportunities and Realities
While the company is accelerating its AI development, the integration of such technology into healthcare environments comes with inherent challenges. Philips' recent industry reports indicate that while AI helps healthcare professionals save significant time—often amounting to weeks of working hours annually—the technology is not a standalone solution. The data highlights that 86% of healthcare professionals believe human oversight remains essential for all AI-generated outputs.
Investors looking at the sector should track how companies like Philips manage the risks associated with AI adoption. These risks include the need for high-quality, long-term medical data, the requirement for consistent training, and the practical challenges of integrating AI into fragmented hospital infrastructures. Future performance for the parent entity will likely depend on its ability to balance rapid technological innovation with the strict safety and regulatory demands of the global healthcare industry.